EUVIMEDEUVIMED entdecken
Crossref

Specific targeting of MR1-antigen complexes using nanobodies

Hisham S Hussain iD, Samuel J Redmond, Wael Awad iD, Calvin Xu iD, Caroline Soliman, Huimeng Wang iD, Yuyang Zhang iD, Lisa Ciacchi iD, Alexis P Gonzalez iD, Jeffrey Y W Mak iD, David P Fairlie iD, James McCluskey iD und 6 weitere

Science Immunology · 2026

DOI: 10.1126/sciimmunol.aeb8726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2026. Verfasst von Hisham S Hussain und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology & Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Histocompatibility Antigens Class I, Minor Histocompatibility Antigens, Mucosal-Associated Invariant T Cells. Die Arbeit nennt 65 Literaturangaben. Gefördert von: National Institutes of Health, Australian Research Council, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell receptor mimic (TCRm) antibodies that bind peptide–human leukocyte antigen complexes have great therapeutic potential. Major histocompatibility complex class I–related protein 1 (MR1) exhibits limited polymorphism and presents conserved metabolites, such as 5-OP-RU, derived from microbial riboflavin biosynthesis. Whether antibodies targeting such MR1–5-OP-RU complexes can be generated remains unclear. Using yeast display technology, nanobodies with high affinity toward the MR1–5-OP-RU complex were generated. These nanobodies can bind both mouse and human MR1–5-OP-RU and inhibit mucosal-associated invariant T (MAIT) cell responses to 5-OP-RU and bacterial challenge, demonstrating in vitro and in vivo bioactivity. We also solved the crystal structures of the lead nanobody in complex with MR1 antigens and demonstrated that the nanobody cobound MR1 and 5-OP-RU, akin to a TCRm antibody. Last, we engineered bispecific antibodies targeting both MR1–5-OP-RU and CD3 that drive broad T cell killing of bacterially infected cells as well as tumor cells treated with 5-OP-RU, providing evidence for immune redirection via MR1-targeting TCRm-based nanobodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesHistocompatibility Antigens Class IMinor Histocompatibility AntigensMucosal-Associated Invariant T CellsAnimalsHumansMice

Substanzen

Single-Domain AntibodiesMR1 protein, humanHistocompatibility Antigens Class IMinor Histocompatibility AntigensMr1 protein, mouse

Autor:innen und Institutionen

  • Department of Microbiology & Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
  • Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
  • Centre for Chemistry and Drug Discovery, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
  • Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.

ORCID-Profile: Hisham S Hussain, Wael Awad, Calvin Xu, Huimeng Wang, Yuyang Zhang, Lisa Ciacchi, Alexis P Gonzalez, Jeffrey Y W Mak, David P Fairlie, James McCluskey, Alexandra J Corbett, Adam P Uldrich, Jamie Rossjohn, Dale I Godfrey, Hui-Fern Koay, Nicholas A Gherardin

Förderung

  • National Institutes of Health
  • Australian Research Council
  • National Health and Medical Research Council

Zitieren

APA

Hussain, H. S., Redmond, S. J., Awad, W., Xu, C., Soliman, C., Wang, H., Zhang, Y., Ciacchi, L., Gonzalez, A. P., Mak, J. Y. W., Fairlie, D. P., McCluskey, J., Corbett, A. J., Uldrich, A. P., Rossjohn, J., Godfrey, D. I., Koay, H. F., & Gherardin, N. A. (2026). Specific targeting of MR1-antigen complexes using nanobodies. Science Immunology. https://doi.org/10.1126/sciimmunol.aeb8726

Vancouver

Hussain HS, Redmond SJ, Awad W, Xu C, Soliman C, Wang H, et al. Specific targeting of MR1-antigen complexes using nanobodies. Science Immunology. 2026. doi:10.1126/sciimmunol.aeb8726

BibTeX
@article{Hussain2026,
  author = {Hussain, Hisham S and Redmond, Samuel J and Awad, Wael and Xu, Calvin and Soliman, Caroline and Wang, Huimeng and Zhang, Yuyang and Ciacchi, Lisa and Gonzalez, Alexis P and Mak, Jeffrey Y W and Fairlie, David P and McCluskey, James and Corbett, Alexandra J and Uldrich, Adam P and Rossjohn, Jamie and Godfrey, Dale I and Koay, Hui-Fern and Gherardin, Nicholas A},
  title = {Specific targeting of MR1-antigen complexes using nanobodies},
  journal = {Science Immunology},
  year = {2026},
  doi = {10.1126/sciimmunol.aeb8726}
}
Kostenlos starten →